FLuGP : OPTIMIZATION OF INFLUENZA VACCINE ANTIGENS PRODUCTION USING REVERSE GENETICS

DESCRIPTION
The laboratory has developed a process to optimize the production rate of Influenza vaccine antigens, to be used either in egg-based and/or cell-culture systems of production. By modifying PR8 genetic background, surface glycoproteins expression of vaccine reassortant virus is increased of +40%. Such a qualitative and quantitative optimization of surface antigen production rate leads to significantly reduce vaccines cost and time of production in manufacturing facilities.

STAGE OF DEVELOPMENT
Proof of concept performed on reassortant PR8 virus expressing H3 and N2 antigens:
• Quantitative analysis of HA/NA surface antigens using cryo-electron microscopy
• Qualitative analysis using NA activity measurements.

ADVANTAGES / NOVELTY
• Increased production rates : more doses per production cycle.
• Decreased production timed.
• Reduction of Influenza vaccines production costs.

APPLICATIONS
Optimization of Influenza vaccine antigens production :
• Egg-based production.
• Cells-based production (cell culture)

INTELLECTUAL PROPERTY
Patent pending in EP, US, CA, CN, JP.
Priority date: July, 13th, 2010 (FR1055716)

COLLABORATION TYPE
PULSALYS looks for industrial partners and offers to grant patent license.

CONTACT
Daphné THOMAS
Tech Transfer Officer
Email: daphne.thomas@pulsalys.fr
Tel: +33(0)4 26 23 56 78